Can China apply for subsidy for Serputinib/Serpatinib?

Selpercatinib is a drug that treats thyroid cancer and non-small cell lung cancer caused by specific gene mutations. Regarding whether you can apply for subsidies in China, patients should contact their local medical insurance agency, hospital or drug supplier to inquire about relevant policies and application requirements. According to the relevant information currently released, Seputinibhas not yet been included in the scope of medical insurance after being launched in China. Patients in need can only purchase this drug at their own expense.

Experimental modeling demonstrates that it has nanomolar potency against a variety of RET alterations, including fusions, activating point mutations, and predicted acquired resistance mutations, while primarily sparing non-RET kinase and non-kinase targets. Seputinib By targeting RET kinase, seputinib blocks signaling pathways associated with tumor growth, reducing tumor cell proliferation, migration, and survival.

Up to now, the original drug is sold in China as SeputinibIt is sold under the name of , and the price of each box of specifications80mg*56 capsules may be more than 10,000 yuan. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). Seputinib is also available overseasSeputinibGeneric drugs are on the market, and their drug ingredients are basically the same as those of original drugs sold domestically and abroad. For example, the specifications produced by Laos Pharmaceutical FactoryThe price of each box of 40mg*120 tablets is more than 4,000 yuan (the price may fluctuate due to the exchange rate).